Mezigdomide (MEZI; CC-92480) in Combination with Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

被引：0
|
作者：
Raab, M. S. [1 ]
Richardson, P. G. [2 ]
Sandhu, I [3 ]
Oriol, A. [4 ,5 ]
White, D. [6 ,7 ]
LeBlanc, R. [8 ]
Perrot, A. [9 ]
Ocio, E. M. [10 ]
Raje, N. [11 ]
Hansen, C. Toftmann [12 ]
Zhou, Z. [13 ]
Civardi, T. [14 ]
Katz, J. [13 ]
Peluso, T. [14 ]
Dimopoulos, M. [15 ]
机构：
[1] Univ Klinikum Heidelberg, Heidelberg, Germany
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Univ Alberta, Edmonton, AB, Canada
[4] Hosp Germans Trias i Pujol, Catalan Inst Oncol Badalona, Badalona, Spain
[5] Josep Carreras Inst, Badalona, Spain
[6] Dalhousie Univ, Halifax, NS, Canada
[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[8] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
[9] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[10] Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain
[11] Massachusetts Gen Hosp, Boston, MA USA
[12] Odense Univ Hosp, Odense, Denmark
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland
[15] Alexandra Gen Hosp, Athens, Greece
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V300
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [1] Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Richardson, Paul
    Sandhu, Irwindeep
    Oriol, Albert
    Raab, Marc S.
    White, Darrell
    LeBlanc, Richard
    Perrot, Aurore
    Ocio, Enrique
    Raje, Noopur
    Hansen, Charlotte Toftmann
    Zhou, Zehua
    Civardi, Tiziana
    Ghiddi, Alessandro
    Katz, Jessica
    Peluso, Teresa
    Dimopoulos, Meletios A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S33 - S33
  • [2] Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc
    White, Darrell
    LeBlanc, Richard
    Raje, Noopur
    Ocio, Enrique
    Perrot, Aurore
    Facon, Thierry
    Rodriguez, Cesar
    Waesch, Ralph
    Amatangelo, Michael
    Zhou, Zehua
    Wang, Yue
    Civardi, Tiziana
    Koo, Philip
    Maciag, Paulo
    Zhu, Daniel
    Katz, Jessica
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S31 - S31
  • [3] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Lonial, Sagar
    Richardson, Paul G.
    Popat, Rakesh
    Stadtmauer, Edward A.
    Larsen, Jeremy T.
    Oriol, A.
    Knop, Stefan
    Jagannath, Sundar
    Cook, Gordon
    Badros, Ashraf Z.
    Rodriguez-Otero, Paula
    Siegel, David S.
    Nguyen, Tuong Vi
    Di Micco, Antonia
    Amin, Alpesh
    Chen, Min
    Kueenburg, Elisabeth
    van de Donk, Niels W. C. J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S9 - S9
  • [4] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Knop, Stefan
    Lonial, Sagar
    Richardson, Paul
    Popat, Rakesh
    Stadtmauer, Edward A.
    Larsen, Jeremy T.
    Oriol, Albert
    Jagannath, Sundar
    Cook, Gordon
    Badros, Ashraf Z.
    Rodriguez-Otero, Paula
    Siegel, David
    Nguyen, Tuong Vi
    Di Micco, Antonia
    Amin, Alpesh
    Chen, Min
    Kueenburg, Elisabeth
    Van De Donk, Niels W. C. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 171 - 171
  • [5] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients with relapsed/refractory multiple myeloma (RRMM)
    Weisel, K.
    Knop, S.
    Lonial, S.
    Richardson, P. G.
    Popat, R.
    Stadtmauer, E. A.
    Larsen, J. T.
    Oriol, A.
    Jagannath, S.
    Cook, G.
    Badros, A. Z.
    Otero, Rodriguez P.
    Siegel, D. S.
    Nguyen, T., V
    Di Micco, A.
    Amin, A.
    Chen, M.
    Kueenburg, E.
    van de Donk, N. W. C. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 86 - 87
  • [6] Initial results of phase 1/2 study CC-92480-MM-002 onCELMoD CC-92480 in combination with bortezomib (BORT)and dexamethasone (DEX) in patients with relapsed /refractory multiple myeloma (RRMM)
    Raab, M. -S.
    Richardson, P. G.
    Ocio, E. M.
    Raje, N.
    Gregory, T.
    White, D.
    Oriol, A.
    Sandhu, I.
    LeBlanc, R.
    Rodriguez Valdes, C.
    Trudel, S.
    Waesch, R.
    Perrot, A.
    Bahlis, N. J.
    Zhou, Z.
    Lamba, M.
    Amatangelo, M.
    Civardi, T.
    Katz, J.
    Maciag, P.
    Peluso, T.
    Dimopoulos, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 86 - 86
  • [7] Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial
    Richardson, Paul G.
    Sandhu, Irwindeep
    Hofmeister, Craig C.
    Orlowski, Robert Z.
    White, Darrell
    Belotti, Angelo
    Hansen, Charlotte Toftmann
    Raje, Noopur S.
    Chow, Tracy T.
    Zhou, Zehua
    Civardi, Tiziana
    Koo, Phillip
    Zhu, Yue
    Katz, Jessica
    Oriol, Albert
    BLOOD, 2023, 142
  • [8] Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
    Orlowski, Robert Z.
    Bahlis, Nizar J.
    Quach, Hang
    Popat, Rakesh
    Lonial, Sagar
    Kim, Kihyun
    Mateos, Maria-Victoria
    Pawlyn, Charlotte
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Casas-Aviles, Ignacio
    Spirli, Alessia
    Gong, Jing
    Amatangelo, Michael
    Katz, Jessica
    Maciag, Paulo
    Peluso, Teresa
    Richardson, Paul G.
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S492 - S493
  • [9] CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002
    Richardson, Paul G.
    Ocio, Enrique
    Raje, Noopur S.
    Gregory, Tara
    White, Darrell
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc-Steffen
    Le Blanc, Richard
    Rodriguez, Cesar
    Trudel, Suzanne
    Waesch, Ralph
    Perrot, Aurore
    Bahlis, Nizar J.
    Zhou, Zehua
    Lamba, Manisha
    Amatangelo, Michael
    Civardi, Tiziana
    Katz, Jessica
    Aciag, Paulo M.
    Peluso, Teresa
    Dimopoulos, Meletios A.
    BLOOD, 2021, 138
  • [10] First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Vangsted, Annette J.
    Ramasamy, Karthik
    Trudel, Suzanne
    Martinez, Joaquin
    Mateos, Maria-Victoria
    Rodriguez Otero, Paula
    Lonial, Sagar
    Popat, Rakesh
    Oriol, Albert
    Karanes, Chatchada
    Orlowski, Robert Z.
    Berdeja, Jesus G.
    Wong, Lilly
    Shi, Chenyang
    Lamba, Manisha
    Barnett, Evelyn
    Pierce, Daniel W.
    Pourdehnad, Michael
    Bahlis, Nizar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345